@drjasonfung Meanwhile $ABBV just reported Q4 earnings, raising 2027 guidance for Skyrizi & Rinvoq to over $31B—a $4B jump from prior projections. Here’s how their US TV ad spend compares to Q revenue.
#Pharma#Healthcare#Biotech#AdSpend#BigPharma
As RFK Jr. faces confirmation today, his proposal to ban TV drug ads could reshape pharmaceutical marketing
In 2024, Skyrizi led all, spending $412M on TV ads.
📊 Watch the monthly top 10 race unfold.
#Pharma#RFKJr#DrugAds#BanPharmaAds#PharmaAds#DTCAdvertising
While the Inflation Reduction Act made steps in Medicare drug negotiations, the data tells us future impact may be limited.
The biggest drivers of Part D spend are already captured in the 2024/2025 selected drugs.
#MedicarePartD#DrugPricing#Pharma#IRANegotiations
Med Part D: Are we hitting the negotiation ceiling?
2024 & 2025 selected drugs account for the bulk of Medicare’s negotiable spending. But what’s left?
Much of the remaining $$ lies in:
1️⃣ Excluded drugs (multi-source)
2️⃣ Lower-spend “eligible” drugs
$LLY $PFE $AMGN $MRK $JNJ
Is #JPM25 the moment you’ve been waiting for?
Your favorite #biotech could be next. But how long does it take to close the deal? 🕒
$KPTI, $VKTX, $MREO, $IOVA, $CYTK, $BPMC, $ZLAB, $RLAY, $EXEL
Source: Press releases, SEC 14D-9 filings
#BiotechDeals
Which #Pharma company is leading in innovation at #JPM25?
With 7 mentions of ‘innovation’ in their presentation, $GSK seems to think they’re the most innovative. Thoughts?
Source: Company transcripts
@neiltyson in the book “astrophysics for people in a hurry” you say after 1 sec the universe was a couple light years across. Wouldn’t that imply that things were traveling much faster than the speed of light?